Evogene (EVGN) Profit After Tax (2012 - 2026)
Evogene (EVGN) posted Profit After Tax of $5.9 million for Q1 2026, up 210.12% sequentially from -$5.4 million in Q4 2025, and up 97.26% YoY from $3.0 million in Q1 2025.
Evogene (EVGN) Profit After Tax (2012 - 2026) Analysis & Trends
Evogene has reported Profit After Tax for 15 years, with the latest figure at $5.9 million in Q1 2026.
- Quarterly Profit After Tax rose 97.26% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (up 192.95% YoY) and the FY2025 annual result came in at -$7.8 million, up 56.65% from the prior year.
- Profit After Tax improved to $5.9 million in Q1 2026 per EVGN's latest filing, from -$5.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at $9.8 million in Q2 2022 and troughed at -$9.1 million in Q1 2022.
- A 5-year average of -$590411.8 and a median of $5000.0 in 2024 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 178.21% in 2025, down 107180.0% in 2025.
- Over 5 years, Profit After Tax stood at $3.8 million in 2022, then tumbled by 292.02% to -$7.3 million in 2023, then surged by 100.07% to $5000.0 in 2024, then sank by 107180.0% to -$5.4 million in 2025, then surged by 210.12% to $5.9 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $5.9 million, -$5.4 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 5.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.90 Mn |
| Dec 31, 2025 | -5.35 Mn |
| Sep 30, 2025 | 5.20 Mn |
| Jun 30, 2025 | 4.68 Mn |
| Mar 31, 2025 | 2.99 Mn |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -8.22 Mn |
| Jun 30, 2024 | -5.99 Mn |
| Mar 31, 2024 | 3.85 Mn |
| Dec 31, 2023 | -7.34 Mn |
| Sep 30, 2023 | -3.86 Mn |
| Jun 30, 2023 | 7.78 Mn |
| Mar 31, 2023 | -6.98 Mn |
| Dec 31, 2022 | 3.82 Mn |
| Sep 30, 2022 | -7.16 Mn |
| Jun 30, 2022 | 9.75 Mn |
| Mar 31, 2022 | -9.11 Mn |
| Dec 31, 2021 | 8.08 Mn |
| Sep 30, 2021 | 8.34 Mn |
| Jun 30, 2021 | 6.90 Mn |